For the Inventor, By the Inventor

Enter assignee name

Pharma Mar, S.a.

USPTO Granted Patents = 93

% Expired Patents = 37.6

CIPO Patents = 12

EPO Patents = 34

Trademarks = 7

Forward Citations = 681

Loading Chart...

Loading Chart...

207 inventors (with patents filed for the assignee):

Ignacio Manzanares (21 out of 22 patents)

Carmen Cuevas (17 out of 18 patents)

Simon Munt (15 out of 15 patents)

4. Dolores Garcia Gravalos (15 out of 32 patents)

5. Pilar Gallego (13 out of 14 patents)

6. Maria Del Carmen Cuevas Marchante (12 out of 12 patents)

7. Andrés Francesch Solloso (10 out of 11 patents)

8. Kenneth L Rinehart (10 out of 46 patents)

9. Glynn Thomas Faircloth (7 out of 14 patents)

10. María Del Carmen Cuevas Marchante (6 out of 6 patents)

11. Marta Perez (6 out of 6 patents)

12. Alberto Rodriguez (6 out of 6 patents)

13. Valentin Martinez Barrasa (6 out of 6 patents)

14. Andrés Francesch (5 out of 6 patents)

15. Anna M Lithgow-Bertelloni (5 out of 5 patents)

Core Competencies:

Antitumoral Compounds

SCLC Treatments

Ecteinascidin Derivatives

Combination Therapy

Cytotoxic Alkaloids

Kahalalide Compositions

Variolin Derivatives

Aplidine

Anticancer Steroidal Lactones

Thiodepsipeptide

Synthetic Methods

Antiviral Compounds

93 patents: Sort by Forward Citations

1. 12714706 - Methods of treating small cell lung cancer with lurbinectedin formulations (2026-08-25),

2. 12653900 - ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES (2026-06-16),

3. 12648986 - PLD for use in combination in the treatment of coronavirus (2026-06-09),

4. 12630589 - Compounds for use in viral infections (2026-05-19),

5. 12440490 - Method of treating SCLC and managing thrombocytopenia (2025-10-14),

6. 12433890 - Method of treating SCLC and managing neutropenia (2025-10-07),

7. 12384800 - Antitumoral compounds (2025-08-12),

8. 12324806 - Method of treating SCLC and managing hepatotoxicity (2025-06-10),

9. 12215100 - Anticancer compounds (2025-02-04),

10. 11713325 - Antitumoral compounds (2023-08-01),

11. 11590129 - Combination therapy with an antitumor alkaloid (2023-02-28),

12. 11339180 - Antitumoral compounds (2022-05-24),

13. 11332480 - Antitumoral compounds (2022-05-17),

14. 11224663 - Antibody drug conjugates (2022-01-18),

15. 10538535 - Antitumoral compounds (2020-01-21),

PharmaMar is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative marine-derived anticancer drugs. With a strong commitment to research and development, PharmaMar aims to improve the lives of cancer patients worldwide through its cutting-edge therapies. The company operates globally, collaborating with leading medical institutions and organizations to advance the field of oncology. For more information about PharmaMar and its groundbreaking work, please visit their website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Pharma Mar, S.a.

93 Patents

#3 in Madrid

#12 in Spain

#8,264 in the World

Pharma Mar, S.a.

Forward Citations = 681

207 inventors:

Ignacio Manzanares (21 out of 22 patents)

Carmen Cuevas (17 out of 18 patents)

Simon Munt (15 out of 15 patents)

4. Dolores Garcia Gravalos (15 out of 32 patents)

5. Pilar Gallego (13 out of 14 patents)

Please report any incorrect information to [email protected]

Loading…